SELF-REPORT CREDIT FORM

Accreditation Statement
This activity has been planned and implemented in accordance with the Essential Areas and Policies of the Accreditation Council for Continuing Medical Education through the joint sponsorship of The Johns Hopkins University School of Medicine and the National Institutes of Health. The Johns Hopkins University School of Medicine is accredited by the ACCME to provide continuing medical education for physicians.

Credit Designation Statement:
The Johns Hopkins University School of Medicine designates this live activity for 1 credit per session for a maximum of 44 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Clinical Center Grand Rounds
Lipsett Amphitheater
12 Noon – 1 p.m.
November 16, 2011

What is New in Thyroid Cancer?
Samuel A. Wells, Jr., M.D., Senior Clinician and Director, Thyroid Oncology Program, Medical Oncology Branch, NCI
Ann Gramza, M.D., Staff Clinician, Thyroid Oncology Program, Medical Oncology Branch, NCI

NOTE: To receive credit for attendance, this form must be returned to the Office of Clinical Research Training and Medical Education by 4 pm on the day of the lecture. Please fax forms to 301-402-2158. For CC Grand Rounds CME inquiries, contact Avril Bertrand at 301-496-9425 or bertranda@cc.nih.gov

<table>
<thead>
<tr>
<th>Date(s)</th>
<th>Maximum Approved Hours per session/per week</th>
<th>Earned Hours</th>
</tr>
</thead>
<tbody>
<tr>
<td>November 16, 2011</td>
<td>1 hour per session/per week</td>
<td>1.0*</td>
</tr>
</tbody>
</table>

Please Print Clearly
Please check one: _____Physician       _____Non-Physician

NAME - LAST       FIRST       MI       PROFESSIONAL DEGREE

NIH BADGE NUMBER (IF NIH EMPLOYEE)

PHONE                          EMAIL                          ORGANIZATION     INSTITUTE/CENTER     DEPT/BRANCH

ADDRESS                        CITY                          STATE                          ZIP + 4

SIGNATURE REQUIRED for ALL ATTENDEES:
I attest that the above number credit hour(s) is correct.

X ____________________________ Date

Signature of Attendee

*These hours will be verified by the Office of Continuing Medical Education (OCME) and recorded on your official Transcript.
FULL DISCLOSURE POLICY AFFECTING CME ACTIVITIES

Clinical Center Grand Rounds – Ethics
Lipsett Amphitheater
Bethesda, Maryland
November 16, 2011

As a provider approved by the Accreditation Council for Continuing Medical Education (ACCME), it is the policy of the Johns Hopkins University School of Medicine Office of Continuing Medical Education (OCME) to require signed disclosure of the existence of financial relationships with industry from any individual in a position to control the content of a CME activity sponsored by OCME. Members of the Planning Committee are required to disclose all relationships regardless of their relevance to the content of the activity. Speakers are required to disclose only those relationships that are relevant to their specific presentation. No relationships have been reported for this activity:

<table>
<thead>
<tr>
<th>SPEAKERS NAME</th>
<th>LECTURE TITLE(S)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Samuel A. Wells, Jr., M.D.</td>
<td>What is New in Thyroid Cancer?</td>
</tr>
<tr>
<td>Ann Gramza, M.D.</td>
<td></td>
</tr>
</tbody>
</table>

No other speakers have indicated that they have any financial interests or relationships with a commercial entity whose products or services are relevant to the content of their presentation(s).

No planner has indicated that they have any financial interests or relationships with a commercial entity

Note: Grants to investigators at The Johns Hopkins University are negotiated and administered by the institution which receives the grants, typically through the Office of Research Administration. Individual investigators who participate in the sponsored project(s) are not directly compensated by the sponsor, but may receive salary or other support from the institution to support their effort on the project(s).

OFF-LABEL PRODUCT DISCUSSION

The following speaker has indicated that he will reference unlabeled/unapproved uses of drugs or products.

<table>
<thead>
<tr>
<th>SPEAKERS NAME</th>
<th>UNAPPROVED/ UNLABELED PRODUCT(S)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Samuel A. Wells, Jr., M.D.</td>
<td>Pazopanib, Sorafenib, Axitinib, Sunitinib, XL184, and Ponatinib</td>
</tr>
</tbody>
</table>

Updated 8/20/07 EJS
Please complete the Continuing Medical Education Questionnaire. To indicate your answers, use the rating scale that is shown by circling the number that represents your answer.

**Scale:**
1 - None or Not at all  2 - Very little  3 – Moderately  4 – Considerably  5 – Completely   N/A - Not applicable

**Speaker: Samuel A. Wells, Jr., M.D.**

**Objective:** Discuss what is known about the molecular pathogenesis of thyroid cancer, and the recently discovered small molecule therapeutics that have proven effective in the treatment of patients with advanced thyroid cancer.

### A. Rating of Objectives and Activity

1. Please rate the attainment of objectives:
   
   a. Define options and alternatives that will guide clinical practice   1     2     3    4     5   N/A
   
   b. Evaluate practical information about clinical research principles based on state-of-the-art information about scientific discovery and clinical advances         1     2      3    4     5   N/A
   
   c. Analyze information and opportunities to increase and improve collaboration between investigators   1     2     3     4    5   N/A

2. The overall quality of the instructional process was an asset to the activity: 1     2      3     4    5   N/A

3. To what extent did participation in this activity enhance your professional effectiveness? 1     2      3     4     5   N/A

4. Will you change your practice in any way as a result of attending this activity? 1     2      3     4     5   N/A

5. Did you perceive any commercial bias? Use the following criteria to judge:
   
   a) The content presented was balanced, evidence-based, demonstrated scientific rigor, and was without commercial bias.  
      If no, please specify: ___________________________________________________   ____No   ____Yes
   
   b) I was informed about the existence and resolution of relevant financial relationships/conflicts of interests of planners and presenters prior to the presentation.  
      If no, please specify: ___________________________________________________   ____No   ____Yes
   
   c) Speakers who discussed off-label, investigational, or alternative uses of products, devices, or techniques disclosed this in their presentation.  
      If no, please specify: ___________________________________________________   ____No   ____Yes

### B. Comments:

1. What comments or suggestions do you have for the faculty presenter(s)?____________________________________________________________________________

2. Are there any other speakers or new topics you would like to have covered in this or a related activity?________________________________________________________________________

3. Do you have additional comments to enhance the utility or impact of the activity?_________________________________________________________________________________

4. May we contact you in several week’s time with a very brief survey to assess the usefulness of this CME activity?  ____Yes   ____No   __ If yes, please provide your email: __________________________
Please complete the Continuing Medical Education Questionnaire. To indicate your answers, use the rating scale that is shown by circling the number that represents your answer.

Scale:
1 - None or Not at all 2 - Very little 3 – Moderately 4 – Considerably 5 – Completely N/A - Not applicable

Speaker: Ann Gramza, M.D.

Objective: Discuss what is known about the molecular pathogenesis of thyroid cancer, and the recently discovered small molecule therapeutics that have proven effective in the treatment of patients with advanced thyroid cancer.

A. Rating of Objectives and Activity

5. Please rate the attainment of objectives:

a. Define options and alternatives that will guide clinical practice 1 2 3 4 5 N/A
b. Evaluate practical information about clinical research principles based on state-of-the-art information about scientific discovery and clinical advances 1 2 3 4 5 N/A
c. Analyze information and opportunities to increase and improve collaboration between investigators 1 2 3 4 5 N/A

6. The overall quality of the instructional process was an asset to the activity: 1 2 3 4 5 N/A

7. To what extent did participation in this activity enhance your professional effectiveness? 1 2 3 4 5 N/A

4. Will you change your practice in any way as a result of attending this activity? 1 2 3 4 5 N/A

5. Did you perceive any commercial bias?
Use the following criteria to judge?

b) The content presented was balanced, evidence-based, demonstrated scientific rigor, and was without commercial bias. ____No _____Yes
If no, please specify: _____________________________

b) I was informed about the existence and resolution of relevant financial relationships/conflicts of interests of planners and presenters prior to the presentation. ____No _____Yes
If no, please specify: _____________________________

c) Speakers who discussed off-label, investigational, or alternative uses of products, devices, or techniques disclosed this in their presentation. ____No _____Yes
If no, please specify: _____________________________

B. Comments:

1. What comments or suggestions do you have for the faculty presenter(s)? _______________________________________

2. Are there any other speakers or new topics you would like to have covered in this or a related activity?
_________________________________________________

3. Do you have additional comments to enhance the utility or impact of the activity?
_________________________________________________

4. May we contact you in several week’s time with a very brief survey to assess the usefulness of this CME activity? ____Yes ____No If yes, please provide your email: ______________________________